Women with rheumatoid arthritis who are of childbearing age face many challenges throughout pregnancy and extending into the postpartum period, from fertility to birth outcomes and control of disease. In this article, rheumatologist Emily Littlejohn, DO, MPH, discusses special considerations for managing patients with rheumatoid arthritis throughout pregnancy and the postpartum period.
The TRAIL-1 study explores the use of pirfenidone, an antifibrotic agent approved for idiopathic pulmonary fibrosis, in patients with rheumatoid arthritis-associated interstitial lung disease.
A new study helps physicians understand how patients analyze the costs and benefits of RA treatments so that they can better engage patients in shared decision-making.
Advances in genetics, biologics and understanding of environmental factors are getting us closer to preventing RA in susceptible patients.
Watch as Sirada Panupattanapong, MD, describes a case preliminarily diagnosed as juvenile idiopathic arthritis but later confirmed as synovial hemangioma.
Since patients with chronic systemic inflammatory states may be at increased risk of developing cardiovascular (CV) disease, the ability to predict which patients with RA or OA that are most likely to experience a major cardiac adverse event (MACE) may help rheumatologists risk stratify these patients early.
An afebrile patient presents with a malar rash, swollen and tender MCP and PIP joints and a positive ANA. What’s the diagnosis?
Intravenous golimumab is both safe and effective over a one-year treatment period for patients with psoriatic arthritis. Rheumatologist Elaine Husnie, MD, MPH, discusses the findings.
Most of the guidelines are conditional but represent the best of evidence-based treatments for psoriatic arthritis.
When might joint pain be Whipple disease? Cleveland Clinic gastroenterologists explain.